| 名稱 | Entinostat |
| 描述 | Entinostat (MS-275) is an HDAC class I selective inhibitor of HDAC1, HDAC2 and HDAC3 (IC50=243/453/248 nM) with oral activity. Entinostat has antitumor activity. |
| 細(xì)胞實(shí)驗(yàn) | Cancer cells (5 × 10^3) were seeded into each well of 96-well plates and were cultured with graded concentrations of the drugs for 3 days. The cells were stained with 0.1 mg/ml neutral red for 1 h in a CO2-incubator, and, after aspiration of the medium, OD540 of the neutral red solubilized with 50 μl of ethanol and 150 μl of 0.1 M Na2HPO4 was measured. The IC50 value was determined by plotting growth inhibition of the cells against the logarithm of the drug concentration [2]. |
| 激酶實(shí)驗(yàn) | The HDAC enzyme activity assay was done as described. Briefly, 40 μl HeLa cell nuclear extract, 29 μl enzyme buffer [15 mM Tris HCl pH 8.1, 0.25 mM EDTA, 250 mM NaCl, 10% (v/v) glycerol]; for recombinant HDAC isoenzymes, 0.1 mg/ml bovine serum albumin (BSA was added) and 1 μl compound were added per well of a microtiter plate. The reaction was started by addition of 30 μl substrate (Ac-NH-GGK(Ac)-AMC final 25 μM). After incubation for 90 min at 30°C, reaction was terminated by adding 25 μl stop solution (50 mM Tris HCl pH 8, 100 mM NaCl, 0.5 mg/ml trypsin, 2 μM TSA). After 40 min incubation at room temperature, fluorescence was measured using a Wallac Victor 1420 multilabel counter (Excitation 355 nm, Emission 460 nm). The HDAC1, 3, 6 and 8 assays were done with slight modifications. About 14 ng/well HDAC1, 2 ng/well HDAC3 or 10 ng/well HDAC6 were incubated with 6, 25 or 10 lM Ac-NH-GGK(Ac)-AMC, respectively, for 2 or 3 hr at 30°C. In contrast, 100 ng/well HDAC8 were incubated with 50 μM Ac-NH-RHK(Ac)K(Ac)-AMC for 3 hr at 30°C. Termination of the reaction and all further steps were done as described earlier for HeLa cell nuclear extracts. For the enzyme kinetic studies with HDAC1, selected HDAC inhibitor (around IC50 value), as well as Ac-NH-GGK(Ac)-AMC substrate (up to 100 μM) concentrations, were evaluated under standard conditions as described earlier [1]. |
| 動物實(shí)驗(yàn) | A2780 cells (9 × 10^6) grown in vitro were suspended in PBS and were injected subcutaneously into the flank of nude mouse. For the other tumor lines, KB-3-1, HCT-15, 4-1St, Calu-3, St-4, Capan-1, and HT-29, tumors were passaged several times before starting in vivo antitumor testing, and a tumor lump (2–3 mm in diameter) was transplanted subcutaneously into the flank of a nude mouse by using a trocar needle. Treatment (four or five mice in each experimental group) with the drugs was started after the tumors were confirmed to have grown in the body (tumor size, 20–100 mm3). MS-27-275 and compound 2, both dissolved with 0.05 N HCl, 0.1% Tween 80, and 5-fluorouracil (5-FU) and diluted with physiological saline, were administered orally once daily 5 days per week for 4 weeks. Tumor length and width were monitored twice weekly, and tumor volume was calculated as described [2]. |
| 體外活性 | 方法: 多種腫瘤細(xì)胞用 Entinostat 處理 72 h，使用 Resazurin solution 檢測細(xì)胞活力。
結(jié)果: Entinostat 抑制腫瘤細(xì)胞增殖，平均 IC50 為 2.57 μM。[1]
方法: 人胰腺癌細(xì)胞 PANC-1 和 SUIT2 Clone 1 用 Entinostat (1-50 μM) 處理 72 h，使用 Western Blot 方法檢測靶點(diǎn)蛋白表達(dá)水平。
結(jié)果: Entinostat 引起細(xì)胞組蛋白 H3 乙?；膭┝恳蕾囆栽黾樱瑢偨M蛋白 H3 蛋白水平?jīng)]有影響，證實(shí)了 Entinostat 抑制癌癥細(xì)胞系中 HDAC 的去乙?；钚?。[2] |
| 體內(nèi)活性 | 方法: 為檢測體內(nèi)抗腫瘤活性，將 Entinostat (12.5-49 mg/kg，0.05 N HCl+0.1% Tween 80) 口服給藥給攜帶人類腫瘤異種移植物的 nude 小鼠，每周五次，持續(xù)四周。
結(jié)果: 49 mg/kg的 Entinostat 對 KB-3-1、4-1St 和 St-4 腫瘤系顯示出顯著的抗腫瘤作用，對 Capan-1 腫瘤顯示出中等的作用。24.5 mg/kg 和 12.3 mg/kg 的藥物對這些腫瘤也顯示出顯著的效果。24.5 mg/kg 的劑量對 A2780 和 HT-29 也顯著有效，對 Calu-3 也中等有效。[3] |
| 存儲條件 | store at low temperature,keep away from moisture,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | DMSO : 16.67 mg/mL (44.28 mM)
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 3.76 mg/mL (9.99 mM), Please add co-solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately.
|
| 關(guān)鍵字 | MS275 | HDAC | Entinostat | Apoptosis | SNDX 275 | Inhibitor | inhibit | SNDX275 | Autophagy | MS 275 | Histone deacetylases |
| 相關(guān)產(chǎn)品 | Guanidine hydrochloride | Naringin | Valproic Acid | L-Glutamic acid | Gefitinib | Hydroxychloroquine | Dextran sulfate sodium salt (MW 4500-5500) | Stavudine | Tributyrin | L-Ascorbic acid | Paeonol | Sodium 4-phenylbutyrate |
| 相關(guān)庫 | 抑制劑庫 | 抗癌上市藥物庫 | 經(jīng)典已知活性庫 | 抗癌活性化合物庫 | 抗衰老化合物庫 | 藥物功能重定位化合物庫 | 抗癌藥物庫 |